Windtree Therapeutics INC: directors' dealings · United States · SEC (Form 4)

About Windtree Therapeutics INC

Windtree Therapeutics Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market under the ticker WINT. Headquartered in Warrington, Pennsylvania, in the United States, the company historically built its profile around the development of therapies for severe cardiovascular and pulmonary conditions. Its principal executive offices house corporate administration, research and drug development, clinical operations, regulatory affairs, and quality functions, while the company also maintains an office in Taipei, Taiwan to support certain manufacturing-development and preclinical activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm)) From a business model perspective, Windtree has evolved from a focused respiratory/cardiopulmonary biotech into a more diversified development-stage company. Its lead product candidate is istaroxime, a first-in-class investigational drug being developed for cardiogenic shock and acute heart failure. The company’s earlier portfolio also included aerosolized KL4 surfactant assets such as lucinactant/AEROSURF, and its SEC filings show additional intellectual property and development work in areas such as rostafuroxin and early-stage oncology. That breadth matters, because Windtree’s economics are still driven primarily by pipeline optionality rather than recurring commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm)) In competitive terms, Windtree remains a small-cap biotech with a high-risk, event-driven valuation profile. Its market position is not defined by scale or commercial market share, but by the potential clinical differentiation of istaroxime and by the company’s ability to fund development, secure partnerships, and convert assets into revenue-generating opportunities. Management has explicitly stated that istaroxime may offer a differentiated safety profile versus current therapies and has emphasized the unmet medical need in cardiogenic shock. That positioning is important, but it should be viewed through the lens of a development-stage company where regulatory milestones and capital access are decisive. ([sec.gov](https://www.sec.gov/Archives/edgar/data/946486/000143774925012093/wint20241231_10k.htm)) Recent developments point to a notable strategic shift. In January 2025, Windtree launched a new corporate strategy aimed at becoming a revenue-generating biotech through acquisitions of small companies and FDA-approved products, while continuing to advance its cardiovascular and oncology pipeline. In May and June 2025, the company reported first-quarter results and highlighted positive publication data for istaroxime in early cardiogenic shock, including progress on the SEISMiC C study. Windtree also entered into a March 2025 license and supply agreement with Evofem to supply Phexxi outside the United States, adding a commercial element to the story. Separately, 2025 press releases showed the company pursuing an unconventional BNB crypto treasury strategy, underscoring a corporate profile that is more dynamic—and more speculative—than a traditional biotech. ([ir.windtreetx.com](https://ir.windtreetx.com/news-releases/news-release-details/windtree-therapeutics-reports-first-quarter-2025-financial?utm_source=openai))